ASX Health Stocks: Oneview extends software deal, LCT to start using AI technology

  • Oneview extends supply agreement to BJC hospital beds
  • LCT will start using artificial intelligence in its research
  • Solid FY22 from AFT Pharma

Oneview extends hospital agreement with BCJ Health

Healthcare software company Oneview Healthcare (ASX: ONE) signed an agreement with BJC Health System to provide the Oneview platform to 2,441 additional beds.

The deal represents a 20% increase on an existing deal with BCJ, which now brings the number of beds using Oneview’s platform to 14,283.

As part of this agreement, BJC will also migrate to Oneview’s CXP Cloud Enterprise platform and move all existing deployments to Android hardware.

BCJ and Oneview have been partners since 2016, and the companies extended the partnership into 2021 by hosting a series of joint workshops to assess how technology could support the traditional model of care during a pandemic.

The Oneview platform would be the world’s first and only cloud-based care experience platform. It provides patients with a digital tablet at their bedside that uses real-time information to facilitate the patient’s stay.

“The pandemic has heightened the importance of bedside technology to enable self-service, keep patients, families and clinicians connected, and support hybrid models of care,” said Oneview CEO James Fitter.

“BJC Health System has a clear and innovative vision of how technology can support hospital care in the future with the ‘connected patient room’,” he added.

Oneview share price today:

Living Cell Technologies will use AI technology

Living Cell Technologies (ASX:LCT) enters a new phase, with the application of artificial intelligence to the company’s research to fight against Parkinson’s disease.

According to LCT, the use of AI will ensure that the NTCELL product manufactured for the company’s third clinical trial of NTCELL in Parkinson’s disease is of the highest possible quality.

Specifically, the company will evaluate strategies to ensure that porcine choroid plexus cells selected for encapsulation are of optimal quality.

“This is an exciting step in the making of NTCELL,” said LCT Executive Chairman Professor Bernie Tuch.

“It introduces modern technology to ensure that the product brought to market for clinical use will be of the highest quality, improving the prospects of success.”

LCT stock price today:

Solid FY22 from AFT Pharma

AFT Pharma (ASX:AFP) FY22 full-year operating revenue rose 15.2% to $130.3 million, while its after-tax net profit was $19.8 million from 7 .8 million the previous year.

Australian sales rose 12.3% as the company posted double-digit growth across all channels despite Covid-19 restrictions.

Abroad, strong sales growth was supported by the licensing of Maxigesic IV in the United States to Hikma Pharmaceuticals.

Looking ahead, AFP says it continues to see considerable growth opportunities and has thus increased its licensing and R&D activities.

Based on this, the company says it expects operating profit for the year through March 31, 2023 to be between $27 million and $32 million.

AFT Pharma share price today:


You may be interested in

Comments are closed.